This observation has to be interpreted with caution as our analysis considered first-line and higher line studies as well as studies that did not differentiate the outcome of first- and second-line treated patients.
This analysis considers third-party reimbursement for generic fluticasone and 1 vial of SCIT, as well as the age of the patient at referral and how many months per year the patient requires intranasal steroids.
A two-phase analysis was considered, first a Confirmatory factor analysis (CFA) and then a Structural Equation Modeling (SEM) were conducted to test hypotheses.
In our analysis, we only considered first clutches, that is first breeding event in a nest box of both female and male (if known) within a reproductive season (n = 2273; see Table A1 for details on yearly sample sizes).
Initially, the analysis considered the first two PCs as traits, and the association with markers (MAF ≥ 0.05) was computed by running both GLM and MLM modules.
Among first and second breast cancers, and in situ and invasive cancers, all cases were included; however, the analysis considered whether second cancers occurred in the same breast or in the contralateral one, and the time interval between diagnoses.
A separate analysis considered whether the first reference memory error made in each testing trial was more likely to be to the single, never-baited arm or one of the adjacent, never-baited arms, over each of the eight, four-trial blocks of acquisition.
The first analysis considered the whole population while the second analysis included the subgroup of 166 patients with a genotype.
Secondly, the kinetic analysis, considering a first order reaction, made it possible to calculate the oxidation kinetic constant (0.04 min−1) and showed a heterogeneous distribution of the active biomass along the reactor.
(4.1) The first analysis considered only patients who received a transfusion.
The first analysis considered which linear combination of clinical AP tests contributed significantly to group classification.
